This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.Below is a short synopsis of each part included in this report:Part I: Prostate CancerThe prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.This part is based on the following publication:A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to MarketPart II: Protein Kinase InhibitorsThe protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.This part is based on the following publication:Protein Kinase Therapeutics in Oncology - Where to Commercialize'Part III: AntibodiesThe cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications. This part is based on the following publication:The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of OthersThe report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities* Supporting development of integrative molecule, pathway and disease area strategies* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investmentThis report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and
Antibodies
Published on September 2011
Report Summary
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one
mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual
parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug
development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but
also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Prostate Cancer
The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the
portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer
drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
Part II: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within
the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein
kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.
This part is based on the following publication:
Protein Kinase Therapeutics in Oncology - Where to Commercialize'
Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology
within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug
targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications.
This part is based on the following publication:
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and
Position of Others
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development
strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and
manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are
aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies (From Slideshare) Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing
and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own
organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to
insure that the optimal market conditions exist by the time the products are commercialized.
Table of Content
Key Topics Covered:
Part I: Prostate Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets) 32-383
7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer
Pipeline (187 Drug Target Strategies and 346 Drugs) 384-438
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound
Strategies) 439-485
9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198
Investigators) 486-820
11 Drug Index 822
12 Company Index 831
Figures: Includes 6 Figures
Tables: Includes 257 Tables
Total Number of Pages: 838
Part II: Protein Kinase Inhibitors
5.1 The Scope of this Report 30
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (133 Drug Targets) 36-336
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer
Protein Kinase Therapeutic Pipeline' (200 Drug Target Strategies and 409 Drugs) 337-407
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type (7 Compound
Strategies) 408-495
9 Selecting Cancer Indications for Protein Kinase Therapeutics (57 Different Cancer Indications) 496-649
10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator (160 Investigators)
650-1417
12 Drug Index 1419
13 Company Index 1433
Figures: Includes 6 Figures
Tables: Includes 302 Tables
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies (From Slideshare) Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Total Number of Pages: 1442
Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on
Investment (255 Drug Targets) 39-430
7 Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of
Development (266 Drug Targets Strategies and 531 Antibody Drugs) 431-768
8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications) 769-893
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator (196
Investigators and 531 Antibody Drugs) 894-1,916
10 Disclaimer 1917
11 Drug Index 1918
12 Company Index 1934
Figures: Includes 5 Figures
Tables: Includes 347 Tables
Total Number of Pages: 1,944
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies (From Slideshare) Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 5 002.50 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies (From Slideshare) Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies (From Slideshare) Page 5/5